Austin, TXNCT07445971Now EnrollingIRB Ready

COVID -19 Clinical Trial in Austin, TX

Access cutting-edge covid -19 treatment through this clinical trial at a research site in Austin. Study-provided care at no cost to qualified participants.

Sponsored by ModeX Therapeutics, An OPKO Health Company

Quick Self-Assessment

See if you qualify for this Austin location

Preparing your pre-screening questions…

Expert Care in Austin

Access covid -19 specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related covid -19 treatment provided free

Apply for This Austin Location

Check if you qualify for this covid -19 clinical trial in Austin, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Austin

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Austin site if eligible
  4. 4Begin participation

About This COVID -19 Study in Austin

This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, anti-drug antibodies, and neutralizing activity of MDX2301 administered by intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes in healthy adults and adults at higher risk for severe COVID-19. Participants will receive single IV, IM, and SC doses of MDX2301 or placebo and a repeat IM or SC dose approximately 3 months apart of MDX2301 or placebo.

Sponsor: ModeX Therapeutics, An OPKO Health Company

Who Can Participate

Inclusion Criteria

Healthy Adults
Participant is a healthy male or female, 18 to 64 years of age.
Participant is in good health in the opinion of the investigator. Adults at Higher Risk for Developing Severe COVID-19:
Participant is a male or female, 18 to 64 years of age.
Participant is at higher risk for developing severe COVID-19, with 1 or more of the following risk factors:
Cerebrovascular disease, which affects blood flow to the brain.
Chronic kidney disease
Chronic lung disease
Cardiac disease
Chronic liver disease
Cystic fibrosis
HIV clinically stable on antiretroviral therapy for at least 6 months prior to screening.
Sickle cell disease or thalassemia
Participant is clinically stable with no clinically significant abnormalities.
Participant has not been hospitalized within the 12 months prior to screening or is not expected to be hospitalized during the study due to underlying medical conditions. All Participants
Female participants of childbearing potential must have a negative urine pregnancy test.
Female participants of childbearing potential must agree to follow instructions for a highly effective birth control method.
Participant is able to understand and sign the informed consent form prior to undergoing any study procedures.
Participant is willing and able to comply with scheduled visits and procedures.

Exclusion Criteria

Healthy Adults
Participant has any chronic or significant medical condition that, in the opinion of the investigator, might compromise the participant's safety or interfere with evaluation of the study drug.
Participant has evidence of active HIV, hepatitis B, or hepatitis C infections at screening. Adults at Higher Risk for Severe COVID-19:
Participant has any serious disease, condition, or disorder that, in the opinion of the investigator, might compromise the participant's safety or interfere with evaluation of the study drug or interpretation of study results, or may lead to hospitalization or death within the study period.
Participant has evidence of active hepatitis B or hepatitis C infections at screening. All Participants
Participant has abnormal vital signs, ECG findings, or laboratory values at Screening or Day -1.
Participant tests positive for SARS-CoV-2 infection at screening.
Participant self-reports having COVID-19 or received COVID-19 antiviral for prophylaxis or treatment prior to Day 1.
Participant has received a SARS-CoV-2 vaccine prior to dosing.
Participant has received a monoclonal antibody (mAb) for SARS-CoV-2 or convalescent plasma for SARS-CoV-2 prior to Day 1.
Participant has received or is expected to receive for the duration of the study immunoglobulin, blood-derived products, high-dose systemic corticosteroids, or other immunosuppressant drugs within 6 months prior to Day 1.
Participant is pregnant, breastfeeding, or seeking pregnancy while on the study.
Participant with a known clinically significant bleeding disorder that would prohibit the participant from receiving an IV infusion or IM or SC injection.
Participant had major surgery within 30 days prior to Day 1.
Participant has donated blood prior to screening.
Participant has any skin condition and/or tattoo that may interfere with the evaluation of safety at the injection site.
Participant has a history of alcoholism or illicit drug use prior to screening or a positive test for drugs of abuse at screening or on Day -1.
Participant is a current smoker or user of other nicotine containing products on a daily basis.
Participant has received an investigational product within 30 days prior to Day 1.
Participant has a known hypersensitivity to any components of MDX2301, any of its excipients or closely related compounds. For All Participants, Temporary Exclusions for Randomization on Day 1 if Remains within the Screening Window:
Participant has any acute illness, within 3 days of Day 1.
Participant has vital signs considered by the investigator to be clinically significant prior to study drug administration.
Participant has had close contact with anyone confirmed to have SARS-CoV-2 infection within the 7 days prior to Day 1.
Any acute drug therapy prescribed by a physician within 7 days prior to Day 1.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Austin?

Yes, this clinical trial (NCT07445971) has an active research site in Austin, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

COVID -19 Treatment Options in Austin, TX

If you're searching for covid -19 treatment options in Austin, TX, this clinical trial (NCT07445971) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Austin research site is actively enrolling participants for this clinical trial. You'll receive care from experienced covid -19 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all covid -19 clinical trials near you to find additional studies recruiting in your area.

More COVID-19 Trials in Austin, TX

See all covid-19 clinical trials recruiting in Austin — not just this study.

Browse COVID-19 Trials in Austin →

Browse More Trials by Condition

COVID-19 TrialsAll Conditions →

Ready to Join in Austin?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Austin, TX